Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences shows a robust outlook supported by a significant increase in market share for its HIV drug Biktarvy, which has risen to 52% in the U.S. market, coupled with a revised growth guidance of +5% year-over-year despite facing challenges from Medicare Part D. The acquisition of Pharmasset, enhancing its hepatitis C portfolio, along with effective life-cycle management strategies and promising early-stage immunology programs, reinforces Gilead's potential for sustained sales growth. Additionally, the expanding presence in the oncology market through therapies like Yescarta, Tecartus, and Trodelvy positions Gilead favorably for future revenue increases, with projected sales growth of approximately $500 million by 2026.

Gilead Sciences is facing a negative outlook driven by declining revenues across its key product lines. Sales of Trodelvy have slightly decreased quarter-over-quarter, with the forecast indicating a roughly 10% decline in cell therapy revenues for FY2025 relative to FY2024. Additionally, significant underperformance in Veklury sales, which fell 60% year-over-year, highlights the company's struggle in maintaining revenue due to reduced demand and increased competition, prompting the revision of revenue guidance for this product.